Market Overview

Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories

Related ABT
Benzinga's Top Upgrades
Barclays Upgrades Abbott, Sees 'Selling Overdone'
Boston Arrives Late To The Mitral Valve Party (Seeking Alpha)

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Morgan Stanley noted, “The most challenging quarter of the year is behind the company and we see clarity to acceleration ahead. Consensus under-appreciates margin momentum into 2H14 and 15'. As EPS and revenue move higher into 2Q, shares will follow. Reiterate our OW thesis and $45 target.”

Abbott Laboratories closed on Wednesday at $38.38.

Latest Ratings for ABT

Oct 2015BarclaysUpgradesEqual-weightOverweight
Aug 2015Credit SuisseAssumesOutperform
Aug 2015JefferiesMaintainsHold

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (ABT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters